RNA 분석 시장 - 예측(2026-2031년)

RNA Analysis Market, with a 12.45% CAGR, is projected to increase from USD 5.572 billion in 2025 to USD 11.269 billion in 2031.

The RNA analysis market is a foundational and rapidly expanding segment within the life sciences and diagnostics industry, encompassing a broad suite of technologies and methodologies for studying ribonucleic acid (RNA) molecules. This market is central to modern biomedical research, enabling the exploration of gene expression, regulation, and function. The analysis of coding mRNA, non-coding RNAs, and complex transcriptomes provides critical insights into cellular processes, disease mechanisms, and therapeutic targets. Market growth is propelled by its indispensable role in several high-impact areas: advancing oncology research, responding to infectious disease threats, enabling personalized medicine, and fueling the burgeoning field of RNA-based therapeutic discovery and development.

A primary and powerful driver is the critical role of RNA analysis in oncology. The study of the transcriptome through techniques like RNA sequencing (RNA-Seq) is fundamental to cancer research and precision oncology. It enables the identification of disease-specific gene expression signatures, the discovery of novel biomarkers for diagnosis and prognosis, and the detection of fusion genes and splice variants that drive tumorigenesis. This molecular profiling is essential for understanding tumor heterogeneity, mechanisms of drug resistance, and for developing targeted therapies. The persistent and significant global burden of cancer ensures sustained and growing demand for sophisticated RNA analysis tools to support both basic research and clinical translational efforts.

Concurrently, the market is strongly driven by its application in infectious disease research and outbreak response. The analysis of pathogen RNA is crucial for identifying and characterizing viruses, bacteria, and other infectious agents, understanding their virulence and transmission mechanisms, and tracking genomic evolution. This capability was prominently demonstrated during the COVID-19 pandemic and remains vital for ongoing surveillance of endemic and emerging pathogens. RNA analysis supports vaccine development, antiviral drug discovery, and the study of host-pathogen interactions, making it a critical tool for public health agencies and research institutions worldwide.

The accelerating focus on personalized medicine is a major catalyst for market expansion. The shift toward tailoring medical treatment to the individual characteristics of each patient relies heavily on molecular data. RNA expression profiling is increasingly used to stratify patients, predict treatment response, and identify those most likely to benefit from specific targeted therapies or immunotherapies. This application, particularly prominent in oncology but expanding to other therapeutic areas, creates demand for robust, reproducible, and often clinically validated RNA analysis platforms that can deliver actionable insights to guide therapeutic decisions.

Perhaps the most dynamic growth vector is the explosion in RNA-based therapeutic development. The successful deployment of mRNA vaccines has validated the platform and catalyzed massive investment in a broader spectrum of RNA medicines, including therapeutic mRNAs, RNA interference (RNAi) drugs, antisense oligonucleotides, and CRISPR-based technologies reliant on guide RNAs. The entire lifecycle of these therapeutics-from target identification and validation to pharmacodynamic biomarker assessment and monitoring treatment response-is deeply dependent on advanced RNA analysis. This directly fuels demand for analytical tools, reagents, and services across the biopharmaceutical R&D continuum.

Furthermore, the market benefits from substantial and sustained investment in basic and translational research from both public and private sectors. Government funding agencies, academic institutions, and biotechnology companies are conducting extensive research to unravel the complexities of the transcriptome, understand RNA biology in health and disease, and develop novel analytical methods. These initiatives, often supported by national and international genomics programs, ensure a continuous pipeline of innovation and a high volume of consumption for RNA analysis products and services.

Geographically, North America maintains a dominant market position. This leadership is underpinned by a concentration of leading academic research centers, a robust biotechnology and pharmaceutical sector, substantial R&D funding, and early adoption of cutting-edge genomic technologies. The region's well-developed infrastructure for clinical trials and molecular diagnostics further reinforces its role as the primary hub for advanced RNA analysis applications in both research and developing clinical contexts.

The competitive landscape includes established life science tools companies, specialized genomics firms, and providers of integrated solutions. Key areas of competition and innovation focus on improving the sensitivity, throughput, and multiplexing capabilities of RNA-Seq platforms; simplifying and automating library preparation workflows; reducing costs per sample; and developing user-friendly bioinformatics software for data analysis and interpretation. The ability to offer end-to-end solutions-from sample preparation to data insight-is a significant differentiator.

In conclusion, the RNA analysis market is experiencing robust growth fueled by its central role in addressing some of the most pressing challenges in modern medicine and drug discovery. Its trajectory is inextricably linked to the progress of precision medicine and the RNA therapeutic revolution. Future market development will be shaped by technological advancements that democratize access to high-quality transcriptomic data, the standardization of methods for clinical application, and the continued integration of artificial intelligence for data interpretation. As our understanding of RNA biology deepens and its therapeutic potential is further unlocked, the demand for sophisticated, reliable, and scalable RNA analysis tools will continue to expand, solidifying its status as an essential pillar of 21st-century biomedical science.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

RNA Analysis Market Segmentation

• By Type
• Messenger RNA (mRNA)
• Transfer RNA (tRNA)
• Others
• By Application
• Reagnet
• Kits
• Enzymes
• Others
• By End-User
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. RNA ANALYSIS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Messenger RNA (mRNA)
• 5.3. Transfer RNA (tRNA)
• 5.4. Others

6. RNA ANALYSIS MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Reagnet
• 6.3. Kits
• 6.4. Enzymes
• 6.5. Others

7. RNA ANALYSIS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Academic & Research Institutes
• 7.4. Others

8. RNA ANALYSIS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Promega Corporation
• 10.2. Lexogen
• 10.3. Zymo Research
• 10.4. Azenta US, Inc
• 10.5. Shimadzu
• 10.6. Cofactor Genomics
• 10.7. Parse Biosciences
• 10.8. CD Genomics
• 10.9. Thermo Fisher Scientific Inc.
• 10.10. Illumina, Inc.
• 10.11. F. Hoffmann-La Roche Ltd
• 10.12. QIAGEN
• 10.13. Bio-Rad Laboratories, Inc.
• 10.14. Danaher Corporation
• 10.15. Agilent Technologies, Inc

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations